Literature DB >> 2147360

Mithramycin selectively inhibits the transcriptional activity of a transfected human c-myc gene.

R Ray1, S Thomas, D M Miller.   

Abstract

The G-C specific DNA binding drug mithramycin selectively inhibits expression of the c-myc gene in a number of cell types. We have tested the ability of this agent to inhibit the expression of a transfected human c-myc gene in a murine fibroblast cell line. Expression of c-myc is inhibited in the first 24 hours of mithramycin exposure (in contrast to actin gene expression, which is unaffected). Nuclear runon transcription of c-myc by nuclei isolated from mithramycin treated cells is decreased, indicating inhibition of transcription initiation. However, treatment of isolated nuclei with mithramycin also results in decreased c-myc transcription. Thus, inhibition of c-myc expression by mithramycin in these cells appears to occur at the transcriptional level and is most likely mediated at both the transcription initiation and elongation level. This suggests that mithramycin selectively interacts with the G-C rich c-myc promoter, preventing formation of the c-myc transcription initiation complex.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147360     DOI: 10.1097/00000441-199010000-00001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

1.  Physical and functional sensitivity of zinc finger transcription factors to redox change.

Authors:  X Wu; N H Bishopric; D J Discher; B J Murphy; K A Webster
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

2.  Zip14 expression induced by lipopolysaccharides in macrophages attenuates inflammatory response.

Authors:  Ahmed Sayadi; Anh-Tuan Nguyen; Frederic A Bard; Emilie A Bard-Chapeau
Journal:  Inflamm Res       Date:  2012-10-02       Impact factor: 4.575

3.  Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway.

Authors:  Lily L Remsing; Jose Garcia-Bernardo; Ana Gonzalez; Eva Künzel; Uwe Rix; Alfredo F Braña; Daniel W Bearden; Carmen Méndez; Jose A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2002-02-27       Impact factor: 15.419

4.  Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.

Authors:  S W Blume; R C Snyder; R Ray; S Thomas; C A Koller; D M Miller
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.

Authors:  Veronica Albertini; Aklank Jain; Sara Vignati; Sara Napoli; Andrea Rinaldi; Ivo Kwee; Mohammad Nur-e-Alam; Julia Bergant; Francesco Bertoni; Giuseppina M Carbone; Jürgen Rohr; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2006-03-29       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.